Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 3/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.43 |
| ▸ | CLK2 | P49760 | 3/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.43 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.43 |
| ▸ | PAK4 | O96013 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3951152 | 0.85 | RAB9A (0.49) | KDRRAB9ANPC1SMN1; SMN2RXFP1 | |
| SCHEMBL3957717 | 0.85 | RAB9A (0.50) | KDRRAB9ANPC1SMN1; SMN2RXFP1 | |
| SCHEMBL3903732 | 0.81 | KDR (0.73) | KDRRAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL3891347 | 0.80 | KDR (0.75) | KDRRAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL13867806 | 0.80 | KDR (0.67) | KDRRAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL187444 | 0.80 | KDR (0.72) | KDRRAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL13867812 | 0.80 | KDR (0.64) | KDRRAB9ANPC1SMN1; SMN2HPGD | |
| Hydrochloric Acid SCHEMBL3896569 | 0.80 | KDR (0.74) | KDRRAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL13867837 | 0.80 | KDR (0.80) | KDRRAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL3891696 | 0.79 | KDR (0.66) | KDRRAB9ANPC1SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247430-B2 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-7507748-B2 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-20060040966-A1 | e.g. 2-(7-isoquinolinylamino)-N-(3-methyl-4-(1-methylethyl)phenyl)-3-pyridinecarboxamide; Vascular Endothelial Growth Factor antagonist; angiogenesis inhibitor; anticarcinogenic, antiinflammatory inhibitor; retinopathies, rheumatoid arthritis, asthma, atherosclerosis, endometriosis, neoplastic diseases | AMGEN INC. | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040966-A1 | e.g. 2-(7-isoquinolinylamino)-N-(3-methyl-4-(1-methylethyl)phenyl)-3-pyridinecarboxamide; Vascular Endothelial Growth Factor antagonist; angiogenesis inhibitor; anticarcinogenic, antiinflammatory inhibitor; retinopathies, rheumatoid arthritis, asthma, atherosclerosis, endometriosis, neoplastic diseases | EDNRA, PTGIS, EDNRB | KDR 4/4885RAB9A 1420/4885NPC1 2638/4885 |
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | FLT1, FLT4, NAT1 | KDR 4/4885RAB9A 2278/4885NPC1 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.